MA35662B1 - Administration d'un inhibiteur d'enzyme activant nedd8 et agent d'hypométhylation - Google Patents

Administration d'un inhibiteur d'enzyme activant nedd8 et agent d'hypométhylation

Info

Publication number
MA35662B1
MA35662B1 MA37066A MA37066A MA35662B1 MA 35662 B1 MA35662 B1 MA 35662B1 MA 37066 A MA37066 A MA 37066A MA 37066 A MA37066 A MA 37066A MA 35662 B1 MA35662 B1 MA 35662B1
Authority
MA
Morocco
Prior art keywords
administration
enzyme inhibitor
activating enzyme
treatment
hypomethylation agent
Prior art date
Application number
MA37066A
Other languages
English (en)
Inventor
Peter G Smith
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MA35662B1 publication Critical patent/MA35662B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des procédés pour le traitement du cancer dans des patients en besoin reconnu d'un tel traitement. Les procédés comprennent l'administration à un tel patient d'un inhibiteur de nae ou d'un sel pharmaceutiquement acceptable de celui-ci, tel que le sulfamate de ((1s,2s,4r)-4-(4-((1s)-2,3-dihydro-1h-indén-1-ylamino)-7h-pyrrolo[2,3 d]pyrimidin 7-yl)-2-hydroxycyclopentyl)méthyle (mln4924) ou le sulfamate de {(1s,2s,4r)-4-[(6-{[(1r,2s)-5-chloro-2 méthoxy-2,3-dihydro-1h-indén-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}-méthyle (i-216), et un agent d'hypométhylation ou un sel pharmaceutiquement acceptable de celui-ci, tel que l'azacitidine ou la décitabine. L'invention porte également sur des médicaments destinés à être utilisés dans le traitement du cancer.
MA37066A 2011-11-03 2014-05-26 Administration d'un inhibiteur d'enzyme activant nedd8 et agent d'hypométhylation MA35662B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161555049P 2011-11-03 2011-11-03
PCT/US2012/063382 WO2013067396A2 (fr) 2011-11-03 2012-11-02 Administration d'un inhibiteur d'enzyme activant nedd8 et agent d'hypométhylation

Publications (1)

Publication Number Publication Date
MA35662B1 true MA35662B1 (fr) 2014-11-01

Family

ID=48193039

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37066A MA35662B1 (fr) 2011-11-03 2014-05-26 Administration d'un inhibiteur d'enzyme activant nedd8 et agent d'hypométhylation

Country Status (22)

Country Link
US (2) US8980850B2 (fr)
EP (1) EP2773360B1 (fr)
JP (2) JP6231988B2 (fr)
KR (1) KR101987861B1 (fr)
CN (1) CN104245699B (fr)
AU (1) AU2012321106C1 (fr)
BR (1) BR112014010699B1 (fr)
CA (1) CA2854461C (fr)
EA (1) EA028380B1 (fr)
ES (1) ES2668272T3 (fr)
GE (1) GEP20196940B (fr)
HK (1) HK1201733A1 (fr)
IL (1) IL232353B (fr)
MA (1) MA35662B1 (fr)
MX (1) MX357835B (fr)
MY (1) MY176125A (fr)
PL (1) PL2773360T3 (fr)
SG (1) SG11201401895WA (fr)
TN (1) TN2014000194A1 (fr)
TR (1) TR201807342T4 (fr)
UA (1) UA114414C2 (fr)
WO (1) WO2013067396A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104016987A (zh) 2009-05-14 2014-09-03 米伦纽姆医药公司 氨基磺酸((1s,2s,4r)-4-{4-[(1s)-2,3-二氢-1h-茚-1-基氨基]-7h-吡咯并[2,3-d]嘧啶-7-基}-2-羟基环戊基)甲酯盐酸盐
MX2014002015A (es) * 2011-08-24 2014-03-27 Millennium Pharm Inc Inhibidores de la enzima activadora de nedd8.
EP2764866A1 (fr) * 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibiteurs de l'enzyme activant nedd8
WO2014186388A2 (fr) 2013-05-14 2014-11-20 Millennium Pharmaceutcals, Inc. Administration d'inhibiteur d'enzyme d'activation de la nedd8 et d'agents chimiothérapeutiques
EP3024488A1 (fr) * 2013-07-26 2016-06-01 Boehringer Ingelheim International GmbH Volasertib en combinaison avec de l'azacitidine pour le traitement de la leucémie aiguë myéloïde et du syndrome myélodysplasique ii
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
CN103948590A (zh) * 2014-05-22 2014-07-30 中国药科大学 Nedd8激活酶抑制剂及其医药用途
MX2018004599A (es) * 2015-10-15 2018-09-21 Celgene Corp Terapia de combinacion para el tratamiento de neoplasias malignas.
WO2018218119A1 (fr) * 2017-05-25 2018-11-29 The Board Of Trustees Of The Leland Stanford Junior University Combinaison d'une faible dose d'il-2 et d'un inhibiteur de la désensibilisation treg il-2 r pour traiter des maladies inflammatoires auto-immunes et allergiques
WO2019060536A1 (fr) * 2017-09-21 2019-03-28 Millennium Pharmaceuticals, Inc. Formes co-cristallines de ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-indén-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)méthylsulfamate, leurs formulations et utilisations
EP3883597A2 (fr) * 2018-11-20 2021-09-29 Fulcrum Therapeutics, Inc. Compositions et méthodes pour augmenter l'hémoglobine foetale et pour traiter la drépanocytose
CN114144230B (zh) 2019-03-15 2024-04-23 弗尔康医疗公司 作为eed和prc2调节剂的大环唑并吡啶衍生物
WO2023025668A1 (fr) 2021-08-25 2023-03-02 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune Méthodes pour la génération de lymphocytes t à mémoire de cellules souches pour une thérapie adoptive par lymphocytes t
WO2023242235A1 (fr) * 2022-06-14 2023-12-21 Scandion Oncology A/S Inhibiteur d'abcg2 et inhibiteur de nae pour le traitement du cancer
CN115007323B (zh) * 2022-06-17 2024-01-23 中南大学 一种抑制矿物中黄铁矿浮选的方法
WO2024012414A1 (fr) * 2022-07-11 2024-01-18 Westlake University Utilisation d'un inhibiteur spécifique de fbxo42 dans le traitement d'une maladie dépendante de la signalisation notch

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US20060063735A1 (en) 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
DK1848718T3 (da) 2005-02-04 2012-08-27 Millennium Pharm Inc E1 aktiveringsenzymhæmmere
EA031335B1 (ru) 2006-02-02 2018-12-28 Миллениум Фармасьютикалз, Инк. Производные пирролопиримидинов
JP5274460B2 (ja) * 2006-08-08 2013-08-28 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｅ１活性化酵素のインヒビターとして有用なヘテロアリール化合物
WO2008028193A2 (fr) 2006-09-01 2008-03-06 Pharmion Corporation Formulations orales d'analogues de cytidine administrées dans le côlon
CA2742252A1 (fr) 2007-11-01 2009-05-07 Celgene Corporation Analogues de la cytidine destines au traitement de syndromes myelodysplasiques
WO2009106549A2 (fr) * 2008-02-26 2009-09-03 Nerviano Medical Sciences S.R.L. Combinaison antitumorale comprenant un dérivé de morpholinyle anthracycline et des agents de déméthylation
EP2299984B1 (fr) 2008-05-15 2018-11-28 Celgene Corporation Formulations orales d'analogues de cytidine et leurs procédés d'utilisation
EP2307002B1 (fr) * 2008-06-09 2013-01-02 Cyclacel Limited Combinaison de sapacitabine ou cndac et d'inhibiteurs d'adn methyltransferase tels que la decitabine et la procaïne
BRPI1013698A2 (pt) * 2009-03-23 2016-04-26 Ambit Biosciences Corp métodos para tratamento com o uso de terapia de combinação
CN104016987A (zh) 2009-05-14 2014-09-03 米伦纽姆医药公司 氨基磺酸((1s,2s,4r)-4-{4-[(1s)-2,3-二氢-1h-茚-1-基氨基]-7h-吡咯并[2,3-d]嘧啶-7-基}-2-羟基环戊基)甲酯盐酸盐
WO2012106299A1 (fr) 2011-01-31 2012-08-09 Celgene Corporation Compositions pharmaceutiques d'analogues de cytidine et leurs méthodes d'utilisation
SG11201401946QA (en) 2011-11-01 2014-05-29 Celgene Corp Methods for treating cancers using oral formulations of cytidine analogs

Also Published As

Publication number Publication date
JP2015505816A (ja) 2015-02-26
BR112014010699A2 (pt) 2017-04-25
NZ624881A (en) 2016-10-28
GEP20196940B (en) 2019-01-10
EP2773360A2 (fr) 2014-09-10
CA2854461A1 (fr) 2013-05-10
HK1201733A1 (en) 2015-09-11
BR112014010699B1 (pt) 2020-12-15
PL2773360T3 (pl) 2018-09-28
AU2012321106A1 (en) 2013-05-23
MX2014005323A (es) 2014-06-05
EA028380B1 (ru) 2017-11-30
ES2668272T3 (es) 2018-05-17
KR101987861B1 (ko) 2019-06-11
EA201400539A1 (ru) 2014-12-30
MY176125A (en) 2020-07-24
JP6231988B2 (ja) 2017-11-15
TR201807342T4 (tr) 2018-06-21
TN2014000194A1 (en) 2015-09-30
CN104245699B (zh) 2017-06-27
AU2012321106C1 (en) 2016-11-24
IL232353A0 (en) 2014-06-30
US20150366886A1 (en) 2015-12-24
WO2013067396A3 (fr) 2014-10-16
IL232353B (en) 2018-11-29
KR20140097229A (ko) 2014-08-06
CN104245699A (zh) 2014-12-24
MX357835B (es) 2018-07-26
EP2773360A4 (fr) 2015-09-23
AU2012321106B2 (en) 2016-08-04
SG11201401895WA (en) 2014-05-29
JP2018009035A (ja) 2018-01-18
US8980850B2 (en) 2015-03-17
US20130116208A1 (en) 2013-05-09
CA2854461C (fr) 2021-01-19
UA114414C2 (uk) 2017-06-12
EP2773360B1 (fr) 2018-02-28
WO2013067396A2 (fr) 2013-05-10

Similar Documents

Publication Publication Date Title
MA35662B1 (fr) Administration d'un inhibiteur d'enzyme activant nedd8 et agent d'hypométhylation
LUC00011I1 (fr)